Skip to main content
Figure 2 | Arthritis Research & Therapy

Figure 2

From: Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort study

Figure 2

Testing of HBV markers before the index date. Distribution of days (x-axis) between the testing of any HBV laboratory marker (hepatitis B surface antigen, hepatitis B core antibody, hepatitis B e antigen, HBV DNA) prior initiation of a new DMARD (index date), stratified by the presence or absence of hepatotoxicity. (ALT>100 IU/mL). Y axis represents a probability density function that any hepatitis B laboratory marker was ordered at each time point.

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us